I agree that this site is using cookies. You can find further informations here.
X
Rai, Shinya
106  results:
Search for persons X
?
1

End-of-treatment 18[F]-FDG PET can predict early progressio..:

Kato, Koji ; Izutsu, Koji ; Nishikori, Momoko...
International Journal of Hematology.  119 (2024)  6 - p. 677-685 , 2024
Link: https://doi.org/10.1007/..
 
?
2

Oral azacitidine compared with standard therapy in patients..:

Dupuis, Jehan ; Bachy, Emmanuel ; Morschhauser, Franck...
The Lancet Haematology.  11 (2024)  6 - p. e406-e414 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Long-term efficacy and safety of tucidinostat in patients w..:

Rai, Shinya ; Kim, Won Seog ; Ando, Kiyoshi...
Haematologica.  , 2024
Link: https://doi.org/10.3324/..
 
?
4

Depletion of Ppp6c in hematopoietic and vascular endothelia..:

Kondo, Ayumi ; Tanaka, Hirokazu ; Rai, Shinya...
Experimental Hematology.  133 (2024)  - p. 104205 , 2024
Link: https://doi.org/10.1016/..
 
?
5

Polatuzumab vedotin in previously untreated DLBCL: an Asia ..:

Song, Yuqin ; Tilly, Hervé ; Rai, Shinya...
Blood.  141 (2023)  16 - p. 1971-1981 , 2023
Link: https://doi.org/10.1182/..
 
?
6

Long-term effectiveness and safety of high dose chemotherap..:

Haeno, Takahiro ; Rai, Shinya ; Miyake, Yoshiaki...
Journal of Clinical and Experimental Hematopathology.  63 (2023)  2 - p. 99-107 , 2023
Link: https://doi.org/10.3960/..
 
?
7

An open-label, single-arm phase 2 trial of valemetostat for..:

Izutsu, Koji ; Makita, Shinichi ; Nosaka, Kisato...
Blood.  141 (2023)  10 - p. 1159-1168 , 2023
Link: https://doi.org/10.1182/..
 
?
8

Distinct Hodgkin lymphoma subtypes defined by noninvasive g..:

Alig, Stefan K. ; Shahrokh Esfahani, Mohammad ; Garofalo, Andrea...
Nature.  625 (2023)  7996 - p. 778-787 , 2023
Link: https://doi.org/10.1038/..
 
?
9

ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphami..:

Flowers, Christopher ; Tilly, Hervé ; Morschhauser, Franck...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S358-S359 , 2022
Link: https://doi.org/10.1016/..
 
?
10

Bendamustine plus rituximab in Japanese patients with relap..:

Murayama, Kayoko ; Kiguchi, Toru ; Izutsu, Koji...
Annals of Hematology.  101 (2022)  5 - p. 979-989 , 2022
Link: https://doi.org/10.1007/..
 
?
11

Two‐year outcomes of tirabrutinib monotherapy in Waldenströ..:

Sekiguchi, Naohiro ; Rai, Shinya ; Munakata, Wataru...
Cancer Science.  113 (2022)  6 - p. 2085-2096 , 2022
Link: https://doi.org/10.1111/..
 
?
12

CD34+ myeloma cells with self-renewal activities are therap..:

Serizawa, Kentaro ; Tanaka, Hirokazu ; Ueda, Takeshi...
International Journal of Hematology.  115 (2022)  3 - p. 336-349 , 2022
Link: https://doi.org/10.1007/..
 
?
13

Poster: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclop..:

Flowers, Christopher ; Tilly, Hervé ; Morschhauser, Franck...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S163 , 2022
Link: https://doi.org/10.1016/..
 
?
14

Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib ..:

Rai, Shinya ; Tanizawa, Yoshinori ; Cai, Zhihong...
Advances in Therapy.  39 (2022)  10 - p. 4792-4807 , 2022
Link: https://doi.org/10.1007/..
 
?
15

Chlorpromazine cooperatively induces apoptosis with tyrosin..:

Fujiwara, Ryosuke ; Taniguchi, Yasuhiro ; Rai, Shinya...
Biochemical and Biophysical Research Communications.  626 (2022)  - p. 156-166 , 2022
Link: https://doi.org/10.1016/..
 
1-15